Donor–Recipient Epstein–Barr Virus Serostatus and Time‐Varying Risk of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients
Transplant Infectious Disease · 2026
DOI: 10.1111/tid.70165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Christie Rampersad und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ajmera Transplant Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Kidney Transplantation, Lymphoproliferative Disorders, Epstein-Barr Virus Infections, Herpesvirus 4, Human. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Prior studies and guidelines emphasize PTLD‐risk for Epstein–Barr virus (EBV) mismatched (D+/R−) recipients. However, risk among D−/R− kidney recipients remains poorly defined. We evaluated PTLD‐risk by donor–recipient EBV serostatus, including D−/R−, and time‐varying impact of PTLD on mortality in kidney transplant recipients.
Methods
This retrospective cohort included deceased donor kidney transplants from the US Scientific Registry of Transplant Recipients (2003–2023). Recipient and donor‐recipient EBV serostatus were categorical exposures. Time‐to‐PTLD was analyzed using Kaplan–Meier methods and adjusted Cox models, stratified into 0–1, 1–2, and 2–3 years to address non‐proportional hazards. Secondary outcomes included mortality and all‐cause graft failure (ACGF), with PTLD modeled as a time‐dependent exposure. Effect modification across key subgroups was evaluated.
Results
Among 309 585 recipients (2.35 million person‐years), 3147 PTLD events (1.1%) occurred, largely within the first year. Incidence was highest for D+/R− (3%) and D−/R− (1.8%) ( p < 0.001). First‐year PTLD‐risk was highest for D+/R− (HR 17.8 [95% CI: 10.4, 30.5]) and D−/R− (HR 8.2 [95% CI: 4.2, 15.8]) recipients. PTLD was associated with increased mortality (HR 4.5 [95% CI: 4.3, 4.8]) and ACGF (HR 3.7 [95% CI: 3.5, 3.9]), with relatively higher mortality‐risk for pediatric recipients (ratio of HRs 1.5). Among 82 detailed PTLD cases, most were B‐cell (89%), monoclonal (63%), and EBV‐positive (78%), with mixed WHO class and site‐involvement.
Conclusions
EBV D+/R− recipients experienced highest and sustained 3‐year PTLD‐risk, while D−/R− recipients faced previously under‐recognized early risk. PTLD was strongly linked to mortality and ACGF, refining counselling and supporting targeted surveillance for high‐risk groups. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ajmera Transplant Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Christie Rampersad, Seyed M Hosseini-Moghaddam, S Joseph Kim
Zitieren
APA
Rampersad, C., Hosseini-Moghaddam, S. M., & Kim, S. J. (2026). Donor–Recipient Epstein–Barr Virus Serostatus and Time‐Varying Risk of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.70165
Vancouver
Rampersad C, Hosseini-Moghaddam SM, Kim SJ. Donor–Recipient Epstein–Barr Virus Serostatus and Time‐Varying Risk of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients. Transplant Infectious Disease. 2026. doi:10.1111/tid.70165
BibTeX
@article{Rampersad2026,
author = {Rampersad, Christie and Hosseini-Moghaddam, Seyed M and Kim, S Joseph},
title = {Donor–Recipient Epstein–Barr Virus Serostatus and Time‐Varying Risk of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients},
journal = {Transplant Infectious Disease},
year = {2026},
doi = {10.1111/tid.70165}
}
EUVIMED